Understanding key healthcare industry issues.
- Contracting, rebating, risk-sharing – IMS Conference hears about more innovative approaches to pricing
This year's IMS Pricing & Market Access European Conference was focused on creative solutions to the issue of pharmaceutical pricing.
Sep 24, 2007
- Vaccines:an antidote to sluggish pharma sales?
As the outlook for their sales improves, a number of Big Pharmas are increasing or beginning their development of vaccines.
Sep 4, 2007
- Why simulation?
The advantages of simulation-based training for the pharmaceutical industry.
Jul 4, 2007
- Lifting the lid on key account management
Changes in the prescribing landscape are driving new sales models based on stronger relationships with key prescribers and their influencers.
Jul 3, 2007
- Is personalised medicine getting closer?
Although many drug companies are still hesitant about developing pharmacogenomic products, work in this area is increasing, particularly for cancer.
Feb 7, 2007
- Fewer NMEs, premium launch prices
IMS’ annual review of Pricing and Market Access reveals the continuing poor state of the industry’s ability to launch novel new drugs.
Oct 5, 2006
- Parallel trade: myth versus reality
IMS’ Janice Haigh separates fact from fiction in the contentious issue of pharmaceutical parallel trading.
May 31, 2006
- Medicare Drug Benefit - Progress Report
One of the biggest changes to hit the US healthcare system was a major topic at the recent IMS Cambridge Pharma Consultancy conference.
Apr 3, 2006
- Maximising pharmaceutical ROI among target segments
Delegates at the 2005 Annual Pharmaceutical Marketing ROI Congress in Amsterdam tried a practical approach for success.
Feb 2, 2006
- The proof is in the prescription: delivering the highest returns for your brand
Companies are investing heavily in promotion, but are they spending their money effectively? IMS examines how to deliver the highest returns for your brand.
Feb 2, 2006
